367 related articles for article (PubMed ID: 23618768)
1. Design and biological evaluation of ⁹⁹mTc-N₂S₂-Tat(49-57)-c(RGDyK): a hybrid radiopharmaceutical for tumors expressing α(v)β(3) integrins.
Ocampo-García BE; Santos-Cuevas CL; De León-Rodríguez LM; García-Becerra R; Ordaz-Rosado D; Luna-Guitiérrez MA; Jiménez-Mancilla NP; Romero-Piña ME; Ferro-Flores G
Nucl Med Biol; 2013 May; 40(4):481-7. PubMed ID: 23618768
[TBL] [Abstract][Full Text] [Related]
2. Multimeric system of 99mTc-labeled gold nanoparticles conjugated to c[RGDfK(C)] for molecular imaging of tumor α(v)β(3) expression.
Morales-Avila E; Ferro-Flores G; Ocampo-García BE; De León-Rodríguez LM; Santos-Cuevas CL; García-Becerra R; Medina LA; Gómez-Oliván L
Bioconjug Chem; 2011 May; 22(5):913-22. PubMed ID: 21513349
[TBL] [Abstract][Full Text] [Related]
3. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
4. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
5. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent.
Zhang X; Chen X
Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200
[TBL] [Abstract][Full Text] [Related]
7. Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3.
Shao G; Zhou Y; Wang F; Liu S
Mol Imaging; 2013; 12(1):39-48. PubMed ID: 23348790
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-labeled RGD-BBN peptide for small-animal SPECT/CT of lung carcinoma.
Liu Z; Huang J; Dong C; Cui L; Jin X; Jia B; Zhu Z; Li F; Wang F
Mol Pharm; 2012 May; 9(5):1409-17. PubMed ID: 22452411
[TBL] [Abstract][Full Text] [Related]
9. microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide.
Wu Y; Zhang X; Xiong Z; Cheng Z; Fisher DR; Liu S; Gambhir SS; Chen X
J Nucl Med; 2005 Oct; 46(10):1707-18. PubMed ID: 16204722
[TBL] [Abstract][Full Text] [Related]
10. Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.
Wang L; Shi J; Kim YS; Zhai S; Jia B; Zhao H; Liu Z; Wang F; Chen X; Liu S
Mol Pharm; 2009; 6(1):231-45. PubMed ID: 19067525
[TBL] [Abstract][Full Text] [Related]
11. Novel 99mTc '4 + 1' peptide conjugates: tuning the biodistribution by variation of coligands.
Kunstler JU; Seidel G; Bergmann R; Gniazdowska E; Walther M; Schiller E; Decristoforo C; Stephan H; Haubner R; Steinbach J; Pietzsch HJ
Eur J Med Chem; 2010 Sep; 45(9):3645-55. PubMed ID: 20570022
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
Janssen ML; Oyen WJ; Dijkgraaf I; Massuger LF; Frielink C; Edwards DS; Rajopadhye M; Boonstra H; Corstens FH; Boerman OC
Cancer Res; 2002 Nov; 62(21):6146-51. PubMed ID: 12414640
[TBL] [Abstract][Full Text] [Related]
13. Technetium-99m-labeled Arg-Gly-Asp-conjugated alpha-melanocyte stimulating hormone hybrid peptides for human melanoma imaging.
Yang J; Guo H; Miao Y
Nucl Med Biol; 2010 Nov; 37(8):873-83. PubMed ID: 21055617
[TBL] [Abstract][Full Text] [Related]
14. Specific uptake of 99mTc-NC100692, an αvβ3-targeted imaging probe, in subcutaneous and orthotopic tumors.
Dearling JL; Barnes JW; Panigrahy D; Zimmerman RE; Fahey F; Treves ST; Morrison MS; Kieran MW; Packard AB
Nucl Med Biol; 2013 Aug; 40(6):788-94. PubMed ID: 23701702
[TBL] [Abstract][Full Text] [Related]
15. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
16. 99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics.
Shi J; Wang L; Kim YS; Zhai S; Jia B; Wang F; Liu S
Eur J Nucl Med Mol Imaging; 2009 Nov; 36(11):1874-84. PubMed ID: 19484236
[TBL] [Abstract][Full Text] [Related]
17. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
18. In vivo imaging of tumour angiogenesis in mice with the alpha(v)beta (3) integrin-targeted tracer 99mTc-RAFT-RGD.
Sancey L; Ardisson V; Riou LM; Ahmadi M; Marti-Batlle D; Boturyn D; Dumy P; Fagret D; Ghezzi C; Vuillez JP
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):2037-47. PubMed ID: 17674000
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.
Liu S; Hsieh WY; Jiang Y; Kim YS; Sreerama SG; Chen X; Jia B; Wang F
Bioconjug Chem; 2007; 18(2):438-46. PubMed ID: 17341108
[TBL] [Abstract][Full Text] [Related]
20. Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides.
Yang Y; Ji S; Liu S
Bioconjug Chem; 2014 Sep; 25(9):1720-9. PubMed ID: 25144854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
